Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Significant progress has been made in prospectively designing molecules using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the analysis reported herein of a second wave of drug candidates that originated after the development and implementation of this tool. This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochemical properties. The CNS MPO tool has helped to increase the percentage of compounds nominated for clinical development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA). The use of this tool has played a role in reducing the number of compounds submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicology into First in Human studies. Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compounds nominated for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
In the citing paper
“Clearly, molecular weight is a physicochemical parameter fundamental for CNS penetration and for the overall profile of drugs against neurodegenerative diseases.103,104”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Self-citationPhysiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Self-citationCNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Self-citationGhose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Development of a new permeability assay using low‐efflux MDCKII cells
Di, L., Whitney‐Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., Lai, Y., Federico, J. J., Davidson, R. E., Smith, R., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22674 · Cited by 313
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Ertl, P. (2007) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621286.ch5 · Cited by 75
In Silico Modeling of Nonspecific Binding to Human Liver Microsomes
Gao, H., Yao, L., Mathieu, H. W., Zhang, Y., Maurer, T. S., Troutman, M. D., Scott, D. O., Ruggeri, R. B., & Lin, J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.020131 · Cited by 68
Probabilistic Approach to Generating MPOs and Its Application as a Scoring Function for CNS Drugs
Gunaydin, H. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00390 · Cited by 55
Wager, T. T., Kormos, B. L., Brady, J. T., Will, Y., Aleo, M. D., Stedman, D. B., Kuhn, M., & Chandrasekaran, R. Y. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401485p · Cited by 42
Self-citation
Research works printed but not linked: 1
- Harrington, E. C., Jr. (1965) The desirability function. Indust. Qual. Control 21, 494-498.
Cited by
Drug discovery with explainable artificial intelligence
Jiménez-Luna, J., Grisoni, F., & Schneider, G. (2020) · Nature Machine Intelligence · doi:10.1038/s42256-020-00236-4 · Cited by 1,063
GuacaMol: Benchmarking Models for de Novo Molecular Design
Brown, N., Fiscato, M., Segler, M. H. S., & Vaucher, A. C. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00839 · Cited by 895
A non-hallucinogenic psychedelic analogue with therapeutic potential
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., et al. (2021) · Nature · doi:10.1038/s41586-020-3008-z · Cited by 473
Challenges and Opportunities in Cancer Drug Resistance
Ward, R. A., Fawell, S., Floc’h, N., Flemington, V., McKerrecher, D., & Smith, P. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00383 · Cited by 445
The Synthesizability of Molecules Proposed by Generative Models
Gao, W., & Coley, C. W. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00174 · Cited by 394
Metadata
- Authors
- Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Wager, Travis T.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-03-18
- Volume
- 7
- Issue
- 6
- Pages
- 767-775
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2300160852
- Cited by
- 653
- References
- 13
- Citations by year
- 2026: 104 · 2025: 121 · 2024: 103 · 2023: 75 · 2022: 72 · 2021: 45 · 2020: 37 · 2019: 32 · 2018: 40 · 2017: 19 · 2016: 5
- FWCI
- 30.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- desirability function, drug candidate design, ADME properties, blood-brain barrier permeability, ClogP, topological polar surface area, drug safety, drug discovery
- MeSH terms
- Algorithms, Animals, Biological Transport, Blood-Brain Barrier, Central Nervous System, Humans, Permeability, Drug Design, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.